-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 D8x75Z0OLANvj0WZNexfqNa2IXEdSSvHJZQixtM9InaiTcusf7Cs3P2KcJXp87nj
 +TxUnUjPT0CYhIr5vnXi5w==

<SEC-DOCUMENT>0000943440-05-000434.txt : 20051028
<SEC-HEADER>0000943440-05-000434.hdr.sgml : 20051028
<ACCEPTANCE-DATETIME>20051027214455
ACCESSION NUMBER:		0000943440-05-000434
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20051024
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20051028
DATE AS OF CHANGE:		20051027

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PETMED EXPRESS INC
		CENTRAL INDEX KEY:			0001040130
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-DRUG STORES AND PROPRIETARY STORES [5912]
		IRS NUMBER:				650680967
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			0330

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-28827
		FILM NUMBER:		051161227

	BUSINESS ADDRESS:	
		STREET 1:		1441 SW 29 AVENUE
		CITY:			POMPANO BEACH
		STATE:			FL
		ZIP:			33069
		BUSINESS PHONE:		9549794788

	MAIL ADDRESS:	
		STREET 1:		1441 SW 29 AVENUE
		CITY:			POMPANO BEACH
		STATE:			FL
		ZIP:			33069
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k2-1024.txt
<TEXT>



                           UNITED STATES
                SECURITIES AND EXCHANGE COMMISSION
                       Washington, D.C. 20549
                           ____________

                            FORM 8-K
                         CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

  Date of Report (Date of earliest event reported): October 24, 2005
                                                    ----------------


                        PETMED EXPRESS, INC.
       ------------------------------------------------------
       (Exact name of registrant as specified in its charter)

                 Commission file number 000-28827

           FLORIDA                                     65-0680967
- ---------------------------------                  -------------------
  (State or other jurisdiction                       (IRS Employer
of incorporation or organization)                  Identification No.)


1441 S.W. 29th Avenue, Pompano Beach, Florida            33069
- ---------------------------------------------          ----------
  (Address of principal executive offices)             (Zip Code)

Registrant's telephone number, including area code: (954) 979-5995
                                                    --------------
                          Not Applicable
   -------------------------------------------------------------
   (Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K is intended to
simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:

[ ]   Written communications pursuant to Rule 425 under the Securities
      Act

[ ]   Soliciting material pursuant to Rule 14a-12 under the Exchange
      Act

[ ]   Pre-commencement communications pursuant to Rule 14d-2(b) under
      the Exchange Act

[ ]   Pre-commencement communications pursuant to Rule 13e-4(c) under
      the Exchange Act


<PAGE>


Item 7.01   Regulation FD Disclosure

Item 8.01   Other Events

       On October 24, 2005, PetMed Express, Inc. discussed its financial
results for the quarter ended September 30, 2005.  A copy of the
conference call transcript is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.

Item 9.01   Financial Statements and Exhibits

(c)	Exhibits

99.1    Conference call transcript by PetMed Express, Inc. on October
        24, 2005


<PAGE>


                           SIGNATURES


	Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.


PETMED EXPRESS, INC.
(The "Registrant")

Date October 27, 2005

By: /s/  Menderes Akdag
   ---------------------------
   Menderes Akdag

   Chief Executive Officer
   (principal executive officer)

By: /s/  Bruce S. Rosenbloom
   ---------------------------
   Bruce S. Rosenbloom

   Chief Financial Officer
   (principal financial and accounting officer)



<PAGE>


                           EXHIBIT INDEX

Exhibit No.                      Description
- ----------                       -----------

   99.1      Conference call transcript by PetMed Express on
             October 24, 2005


<PAGE>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>form8k2-ex991.txt
<TEXT>

                            EXHIBIT 99.1

                        PETMED EXPRESS, INC.
               QUARTER ENDED SEPTEMBER 30, 2005
                  CONFERENCE CALL TRANSCRIPT
               OCTOBER 24, 2005 AT 8:30 A.M. EDT

Coordinator	Welcome to the PetMed Express Inc. doing business as
                1-800-PetMeds conference call to review the financial
                results for the 2nd fiscal quarter ended on September
                30, 2005.  Due to Hurricane Wilma, this conference
                call has been prerecorded, and there will not be a
                question and answer session following the
                presentation.

                Founded in 1996, 1-800-PetMeds is America's Largest
                Pet Pharmacy, delivering prescription and non-
                prescription pet medications, and other health
                products for dogs, cats and horses direct to the
                consumer.  1-800-PetMeds markets its products through
                national television, on-line and direct mail
                advertising campaigns, which direct consumers to order
                by phone or on the internet, and aim to increase the
                recognition of the "1-800-PetMeds" brand name.  1-800-
                PetMeds provides an attractive alternative for
                obtaining pet medications in terms of convenience,
                price, ease of ordering and rapid home delivery.

                At this time I would like to turn the call over to the
                Company's Chief Financial Officer, Mr. Bruce
                Rosenbloom.

B. Rosenbloom	I would like to welcome everybody here today.  Before
                I turn the call over to Mendo Akdag, our Chief
                Executive Officer and President, I would like to
                remind everyone that the entire conference call will
                be listen-only, and there will not be a question and
                answer session following the presentation.

                Also, certain information that will be included in
                this press conference may include forward-looking
                statements within the meaning of the Private
                Securities Litigation Reform Act of 1995 or the
                Securities and Exchange Commission that may involve a
                number of risks and uncertainties. These statements
                are based on our beliefs, as well as assumptions we
                have used based upon information currently available
                to us. Because these statements reflect our current
                views concerning future events, these statements
                involve risks, uncertainties and assumptions.  Actual
                future results may vary significantly based on a
                number of factors that may cause the actual results or
                events to be materially different from future results,
                performance or achievements expressed or implied by
                these statements. We have identified various risk
                factors associated with our operations in our most
                recent annual report and other filings with the
                Securities and Exchange Commission.

                Now let me introduce today's speaker, Mendo Akdag,
                Chief Executive Officer and President of 1-800-
                PetMeds.

M. Akdag	Welcome and thank you for joining us. Today we will
                review the highlights of our financial results. We
                will compare our 2nd fiscal quarter and six months
                ended on September 30, 2005 to last year's quarter and
                six months ended on September 30, 2004.

                For the 2nd fiscal quarter ended on September 30, 2005,
                sales were $38.7 million compared to sales of $28.8
                million for the same period the prior year, an
                increase of 34%. For the six months ended on September
                30, 2005, sales were $82.3


                          Exhibit 99.1 Page 1 - 3

<PAGE>



                million compared to $64.0 million for the six months
                the prior year, an increase
                of 28%. The increase was primarily due to increased
                retail reorders, retail new orders and wholesale
                sales. It was a hot summer with a favorable
                advertising environment. Compared to last year, our
                advertising was more efficient and effective and
                included more discount offers.

                For the 2nd fiscal quarter, Net Income was $2.7
                million, or $0.11 diluted per share compared to $1.8
                million, or $0.08 diluted per share for the same
                quarter the prior year, an increase to net income of
                50%. For the six months, net income was $6.3 million,
                $0.26 diluted per share compared to $3.6 million,
                $0.15 diluted per share a year ago, an increase to net
                income of 72%.

                Retail Reorder sales increased by 33% to $22.9 million
                for the quarter compared to retail reorder sales of
                $17.2 million for the same quarter the prior year. For
                the six months, the reorder sales increased by 31% to
                $48.6 million compared to $37.2 million for the same
                period last year.

                Retail New order sales increased by 35% to $14.7
                million for the quarter compared to $10.9 million for
                the same period the prior year. For the six months,
                the new order sales increased by 21% to $31.1 mil
                compared to $25.8 million for the same period last
                year.

                Wholesale sales were $1.1 million for the quarter
                compared to $600,000 for the same quarter the prior
                year. For the six months, wholesale sales were $2.5
                million compared to $1.1 million for the same period a
                year ago.

                We acquired 208,000 new customers in our 2nd fiscal
                quarter compared to 154,000 for the same period the
                prior year, and we acquired 425,000 new customers in
                the six months compared to 345,000 for the same period
                a year ago.

                Our average order was approximately $74 for the
                quarter, and approximately 55% of our sales were
                generated on our web site.

                The seasonality in our business is due to the
                proportion of flea, tick and heartworm medications in
                our product mix. Spring and summer are considered peak
                seasons, with fall and winter being the off seasons.

                For the 2nd fiscal quarter, our Gross Profit as a % of
                sales was 38.4% compared to 40.4% for the same period
                a year ago. For the six months, our gross profit as a
                % of sales was 38.5% compared to 39.8% for the six
                months a year ago.  The percentage decrease can mainly
                be attributed to increases to our product and freight
                costs, discounts given to our customers, and increases
                in wholesale sales, which have lower gross profit
                margin. We were more aggressive with our pricing to
                capture market share.

                Our General & Administrative expenses as a % of sales
                decreased to 9.9% for the quarter compared to 10.3%
                for the same quarter the prior year, and for the six
                months, the G&A decreased to 9.3% compared to 9.7% a
                year ago. The improvement shows a continued leverage
                of the G&A.

                For the quarter, we spent $6.9 million in advertising
                compared to $5.6 million for the same quarter the
                prior year, an increase of 23%. For the six months, we
                spent $14.5 million for advertising compared to $13.4
                million a year ago, an increase of 9%.


                           Exhibit 99.1 Page 2 - 3

<PAGE>

                Advertising cost of acquiring a customer for the
                quarter was $33 compared to $37 for the same quarter
                the prior year, and for the six months it was $34
                compared to $39 for the same period a year ago. The
                improvement is attributable to increased advertising
                efficiency with more effective creatives.

                Our working capital increased by $6.8 mil to $28.8 mil
                since March 31, 2005. The increase can be attributed
                mainly to cash flow generated from operations.
                We had $25.6 million in cash, and $8.4 million in
                inventory with no debt as of September 30, 2005. Net
                cash from operations for the six months was $12.7
                million compared to net cash from operations of $6.6
                million for the same period last year.  Capital
                expenditures for the six months were approximately
                $31,000.

                For the remainder of fiscal 2006, the Company has
                approximately $350,000 planned for capital
                expenditures the majority of which is to expand the
                Company's warehouse, pharmacy and fulfillment
                operations which we anticipate completing by March
                2006.

                In closing, we'll continue focusing our efforts in 3
                areas to capitalize on the pet industry's growth
                trend:

                1.  Optimizing our advertising media buys.

                2.  Improving reorders with health education content to
                    build value for our customers, to differentiate our
                    brand and help our customers choose the right
                    products for their pet's conditions.

                3.  Expanding our product offerings with new private
                    label high-end products with a focus on quality
                    nutritional supplements.

                This wraps up today's conference call.  Thank you for
                joining us.

                Operator, this ends the conference call.


                           Exhibit 99.1 Page 3 - 3

<PAGE>



</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
